Holen Sie sich die Stockscreener-App
46.02
0.11%
-0.05
Vorhandelsmarkt:
45.82
-0.20
-0.43%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
TIAA Trust National Association Reduces Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth - Seeking Alpha
BioNTech Boosts 2025 Outlook as Cancer Drug Alliance with Bristol Myers Squibb Takes Aim at Merck’s Keytruda - Tekedia
Pulmonary Fibrosis Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, A - Barchart.com
Balanced Outlook on Bristol-Myers Squibb: Strong Q3 Performance Amid ADEPT-2 Trial Concerns - TipRanks
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership - inkl
Bristol Myers Squibb to present Camzyos efficacy data at AHA scientific sessions - Investing.com
Bristol-Myers Squibb stock rises 7% after clean earnings beat By Investing.com - Investing.com Nigeria
United States Vitiligo Forecast Report 2025: A $320+ Million Market by 2033 Featuring Incyte, BMS, Clinuvel Pharmaceuticals, Astellas Pharma, Baxter, Pfizer, Dr. Reddy's LaboratoriesResearchAndMarkets.com - Business Wire
US Cancer Immunotherapy Forecast and Company Analysis Report 2025-2033 Featuring Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Pfizer, Novartis, Johnson & Johnson, Eli Lily Co, Seattle GeneticsResearchAndMarkets.com - FinancialContent
Bristol-Myers Squibb stock rises 7% after clean earnings beat - Investing.com
Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades' - Benzinga
Verity Asset Management Inc. Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025 - Business Wire
BioNTech raises 2025 revenue guidance after Bristol Myers deal By Investing.com - Investing.com Nigeria
BioNTech raises 2025 revenue guidance after Bristol Myers deal - Investing.com
BioNTech lifts 2025 revenue guidance on BMS partnership payment - Reuters
BioNTech Raises Sales Outlook on Boost from Bristol Payments - Bloomberg.com
Bristol Myers Squibb Co Announces $7 Billion Cash Tender Offers - TradingView
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes - The AI Journal
Published on: 2025-11-02 22:42:16 - newser.com
How Bristol Myers Squibb Company (BRM) stock moves in volatile trading sessionsQuarterly Risk Review & Weekly Market Pulse Alerts - newser.com
Syverson Strege & Co Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Assetmark Inc. Lowers Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
What’s the recovery path for long term holders of Bristol Myers Squibb Company Equity RightTrade Signal Summary & Technical Pattern Alert System - newser.com
Bristol-Myers Squibb Company (NYSE:BMY) Q3 2025 Earnings Call Transcript - Insider Monkey
Can Bristol Myers Squibb Company stock hit record highs againExit Point & Entry Point Confirmation Signals - newser.com
Bristol Myers Squibb Co. Hits New 52-Week Low at $42.52 - Markets Mojo
Bristol Myers Squibb Company recovery potential after sell offWeekly Market Report & Risk Controlled Daily Trade Plans - newser.com
Is Bristol Myers Squibb Company Celegne Contingent stock a fit for income portfolios2025 Market Overview & Comprehensive Market Scan Insights - newser.com
Bristol-Myers Squibb Company (BMY.MX) stock price, news, quote and history - Yahoo! Finance UK
Bristol Myers Squibb (NYSE:BMY) Posts Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Bristol Myers Squibb Stock Hits Day High with 7.09% Surge - Markets Mojo
S&P 500 Falls 0.99% Amid 1,651 Advancing Stocks; Bristol Myers Soars 7.09% - Markets Mojo
Bristol-Myers Squibb Tops Forecasts But Leaves Questions Unanswered - Finimize
Germ Cell Tumors Market: Epidemiology, Therapies, Companies – DelveInsight | Featuring Takeda, Novartis, Bristol Myers Squibb, Merck & Co., Roche, and Bayer - Barchart.com
Retirement Systems of Alabama Has $60.37 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
New launches focus of latest financial prints at BMS, Merck & Co. - FirstWord Pharma
Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data - Insider Monkey
Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings: Revenue Surpasse - GuruFocus
Bristol-Myers Squibb Shares Rally on Strong Quarterly Performance - AD HOC NEWS
Will Bristol Myers Squibb Company (BRM) stock beat growth indexesBuy Signal & Momentum Based Trading Signals - newser.com
Bristol-Myers Squibb Company (BMY) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Research Alert: CFRA Keeps Buy View On Shares Of Bristol-myers Squibb Company - 富途牛牛
Bristol-Myers Squibb Company (BMY) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Bristol-Myers Sets $160 Million Tax Reserve for Transfer Pricing - news.bloombergtax.com
Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript Summary - 富途牛牛
Bladder Cancer MarketGlobal and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson - Yahoo Finance
BRISTOL MYERS SQUIBB CO SEC 10-Q Report - TradingView
Bristol rises on 2025 guidance raises, Q3 beats driven by Eliquis growth - MSN
Bristol Myers tries to temper anxiety over upcoming Cobenfy readout, unveils suite of PD-1xVEGF bispecific trials - Endpoints News
BMS Battles ‘Deeply Ingrained’ Prescribing Habits in Schizophrenia as Cobenfy Misses Q3 Estimates - BioSpace
December 12th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View - TradingView
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock? - ts2.tech
Bristol Myers Squibb Outpaces Expectations With Strong New Drug Sales - Finimize
Bristol Myers beats quarterly revenue estimates on strong Opdivo sales - Reuters
Earnings call transcript: Bristol-Myers Squibb reports strong Q3 2025 earnings beat - Investing.com
Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewswire Inc.
Bristol Myers: Q3 Earnings Snapshot - News-Times
Bristol-Myers Squibb ups annual outlook as Q3 print exceeds estimates - Investing.com Nigeria
Bristol Myers Beats Quarterly Expectations on Drug Demand - Bloomberg.com
Bristol-Myers Squibb earnings beat by $0.11, revenue topped estimates - Investing.com Canada
1.05%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):